Dhanuka Agritech Ltd Q2FY26 – The ₹6,000 Crore Pesticide Powerhouse That’s Spraying Profit Margins Like Confetti, but Growth Looks a Little Wilted
1. At a Glance
Dhanuka Agritech (NSE: DHANUKA) – the ₹6,252 crore agrochemical veteran – is having one of those “good kid in a tough neighborhood” quarters. The company clocked ₹598 crore in revenue for Q2FY26, down 8.6% YoY, with PAT of ₹94 crore (down 20% YoY). Market clearly wasn’t thrilled — the stock is now lounging at ₹1,370, nearly 30% below its 52-week high of ₹1,975, nursing a hangover from last year’s bumper monsoon season that never came this time.
But before you assume the pesticide party’s over, here’s the punchline: ROCE at 28.3%, ROE at 22%, and debt-to-equity at 0.02 — the company’s balance sheet looks cleaner than your mother’s Diwali showcase. EPS stands tall at ₹61.4, with a dignified P/E of 22.3 against the industry average of 32. Dhanuka’s got the profitability of an FMCG major and the growth mood of an engineer after appraisal season.
In short — this is a company that prints cash, just not press releases full of excitement.
2. Introduction
Once upon a time in Gurgaon, a bunch of agrochemical folks decided to make farming great again. That’s how Dhanuka Agritech, India’s own pesticide prince, came into being. The company sells everything from herbicides that kill weeds faster than gossip spreads in a small town, to fungicides that guard crops better than CRPF at borders.
But FY26 hasn’t exactly been a red-carpet season for Dhanuka. Demand moderation, erratic monsoons, and inventory correction have made rural India act like that one friend who says, “Next month pakka recharge kar lunga.” The numbers reflect it: sales fell 8.6% YoY and PAT slipped 20%.
Still, Dhanuka is the kind of disciplined kid who, even after failing one test, still tops the class average. ROCE of 28% and ROE of 22% in a sector where others are still arguing with their calculators — that’s elite.
Meanwhile, the boardroom drama had its own spicy subplot: acquisition of Bayer AG’s global rights for Iprovalicarb and Triadimenol for ₹160 crore, and a proposed Nagpur formulation plant. Imagine buying an entire pesticide legacy and still calling it “due diligence.”
So, is Dhanuka’s crop still fertile, or are margins drying faster than monsoon rivers? Let’s find out.
3. Business Model – WTF Do They Even Do?
If you’re wondering what Dhanuka sells — it’s basically the “Zandu Balm” for Indian farmers’ headaches. Their product basket of over 300 registrations spans herbicides (35% of sales), insecticides (30%), fungicides (20%), and plant growth regulators (15%). If it crawls, infects, or eats, Dhanuka has a bottle for it.
With 6,500 distributors, 80,000 retailers, and 41 warehouses, they serve more than 10 million farmers — yes, more than the population of Portugal. They even have an in-house R&D setup called DART (Dhanuka Agritech Research & Technology Centre) at Palwal, Haryana, which sounds like Iron Man’s lab but with sprayers instead of suits.
Their secret sauce lies in collaborations — they’ve signed tie-ups with 7 global agrochemical giants from the US, Japan, and Europe, ensuring they bring high-end crop solutions faster than WhatsApp forwards. Recently, they even joined hands with Spain-based Kimitec to build biological crop solutions. Because apparently, “bio” sells better than “chemical” these days.
So yeah — they make stuff that kills pests but saves farmers. Irony and profitability in one spray bottle.
4. Financials Overview
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue
₹598 Cr
₹654 Cr
₹528 Cr
-8.6%
+13.3%
EBITDA
₹137 Cr
₹160 Cr
₹83 Cr
-14.4%
+65.1%
PAT
₹94 Cr
₹118 Cr
₹56 Cr
-20.3%
+67.8%
EPS (₹)
20.6
25.8
12.2
-20.3%
+68.9%
Commentary: The quarter looks like a rainfall chart — down YoY, up QoQ. While topline dipped due to delayed rainfall and channel destocking, EBITDA margin held steady at 23%. Basically, the company’s expense control deserves a standing ovation from CFOs across India.
5. Valuation Discussion – Fair Value Range Only
Method 1: P/E Multiple EPS (TTM): ₹61.4 Industry P/E: 32.2 Dhanuka P/E: 22.3 If re-rated to industry levels: Fair Value = ₹61.4
